Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited
2015 · Acquisition/Merger · $4.0B · Complete
Announcement Sentiment
38
Skeptical
Sun Pharma completed the all-share acquisition of Ranbaxy from Daiichi Sankyo (which held 63.4%) on March 25, 2015 in a $4B transaction (announced April 7, 2014), creating the world's fifth-largest generic drug maker. Each Ranbaxy share exchanged for 0.8 Sun Pharma share.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Dilutive
Pipeline outcome
Mixed
Assessment window: 10yr post-close.
Key facts
AnnouncedMar 25, 2015
ClosedMar 25, 2015
Deal value$4.0B
Deal typeAcquisition/Merger
Therapeutic areaMultiple (broad generics)
IndicationsMultiple (broad generics)
Key assetsGeneric pharmaceuticals portfolio
MechanismGeneric small molecules across therapeutic areas